StudyID,Drug_Name,No_Arm,Randomization,Central_Random,Rand_Ratio,Random_Parallel,Random_Crossover,Random_Fact,Random_Cluster,Stratification,No_Stratification,Single_Arm,Hist_control,Blinding,Level_Blinding,Placebo_control,Active_Control,Control_Drug,Obj_Primary,No_Prim_EP,Primary_EP,Success_Criteria_Text,Primary_EP_SC,Key_Second_EP,Key_Second_EP_SC,IRC,Sample_Size,Power,Alpha,Sided,Subgroup,Interim,Timing_IA,Alpha_Spend_Func,Adaptive_Design,Consistency_Sens_Ana_PE,Consistency_Sens_Ana_SE,Post_Hoc_Ana,Intercurrent_Events,Gatekeeping_Strategy,Reg_Alignment,Fast_Track,Breakthrough,Priority_Review,Accelerated_App,Orphan_Drug,Pediatric,Rare_Disease,Reg_Audit,Consistency_MRCT
NCT01295827,Pembrolizumab,15,Yes,,,Yes,No,No,,,,No,No,No,0,No,No,,,4,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1); Number of Participants Who Experienced an Adverse Event (AE); Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D); ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),,,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),,,,,,,,,,,,,,,,,,,,,,,,,,
